Zimmer Biomet (ZBH) files 8-K, furnishes Q2 2025 earnings press release

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) filed an 8-K dated 7 Aug 2025 to disclose Item 2.02 – Results of Operations and Financial Condition.

Rhea-AI Filing Summary

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) filed an 8-K dated 7 Aug 2025 to disclose Item 2.02 – Results of Operations and Financial Condition.

• The company issued a press release (Exhibit 99.1) announcing its financial results for the quarter ended 30 Jun 2025; the actual figures are not included in the filing.
• The 8-K clarifies that the press release is being furnished, not filed, thereby limiting Exchange Act liability.
• No other material transactions, guidance changes or strategic updates are reported.

The document also lists ZBH’s registered securities (common stock and three note issues) and provides standard emerging-growth-company and signature boilerplate.

Insights

Securities Analyst

TL;DR: Routine 8-K furnishing an earnings press release; no numbers, neutral impact.

The filing simply alerts investors that Zimmer Biomet’s Q2-25 results are available in a separate press release. Because no revenue, EPS or guidance data are presented, the 8-K itself offers minimal analytical value. Liability is limited by furnishing status, a common practice. Market reaction will hinge on the content of Exhibit 99.1, not this notice. I therefore assign a neutral impact rating.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Zimmer Biomet disclose in its 8-K dated August 7 2025?

The company furnished a press release (Exhibit 99.1) reporting financial results for the quarter ended June 30 2025.

Are actual Q2 2025 financial figures included in the 8-K?

No. The 8-K references the press release but does not reproduce revenue, EPS or other metrics.

Does the filing impose Exchange Act liability for the earnings data?

No. The information is furnished, not filed, under Item 2.02, limiting Section 18 liability.

Which securities of Zimmer Biomet are listed in the filing?

Common stock (ZBH) and notes due 2026 (2.425%), 2027 (1.164%), and 2032 (3.518%), all traded on NYSE.

Where can investors find the detailed Q2 2025 results?

In Exhibit 99.1, the press release dated August 7 2025, which accompanies the 8-K filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/07/2025 - 06:30 AM Learn about SEC filing dates

false00011368690001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2025-08-072025-08-0700011368692025-08-072025-08-070001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2025-08-072025-08-070001136869us-gaap:CommonStockMember2025-08-072025-08-070001136869zbh:ThreePointFiveOneEightPercentageNotesDueTwoThousandThirtyTwoMember2025-08-072025-08-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

ZIMMER BIOMET HOLDINGS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-16407	13-4151777
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
345 East Main Street
Warsaw, Indiana				46580
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (574) 373-3333

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		ZBH		New York Stock Exchange
2.425% Notes due 2026		ZBH 26		New York Stock Exchange
1.164% Notes due 2027		ZBH 27		New York Stock Exchange
3.518% Notes due 2032		ZBH 32		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 7, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

EXHIBIT INDEX
Exhibit No.		Description
99.1		Press release dated August 7, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 7, 2025

	ZIMMER BIOMET HOLDINGS, INC.
	By:	/s/ Chad F. Phipps
	Name:	Chad F. Phipps
	Title:	Senior Vice President, General Counsel and Secretary